Core Insights - Lyell Immunopharma, Inc. announced positive clinical data for LYL314, a CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL), showing an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting [1][3][4] Clinical Data Summary - In a Phase 1/2 trial, 25 patients in the 3L+ setting demonstrated an 88% overall response rate and a 72% complete response rate, with 71% of those achieving complete response remaining so at ≥ 6 months [1][3][4] - The efficacy evaluable population included 36 patients, with a median follow-up of 9 months for 3L+ patients and 5 months for 2L patients [2][3] - Among 51 CAR T-naive patients, 70% of those with primary refractory disease achieved a complete response [4] Safety Profile - The safety profile of LYL314 was manageable for outpatient administration, with no Grade ≥ 3 cytokine release syndrome reported and low rates of Grade 1 (22%) and Grade 2 (35%) adverse events [3][5] - Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 6% (Grade 1), 2% (Grade 2), and 14% (Grade ≥ 3) of patients, with a median resolution time of 5 days [5] Ongoing Trials - The pivotal single-arm PiNACLE trial is currently underway, targeting approximately 120 patients with relapsed/refractory LBCL in the third- or later-line setting [6][12] - The trial aims to evaluate the overall response rate as the primary endpoint [12] Regulatory Designations - LYL314 has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for the treatment of relapsed/refractory aggressive B-cell lymphoma [11] Manufacturing and Technology - LYL314 is designed to target B cells expressing either CD19 or CD20, utilizing a proprietary manufacturing process to enhance T-cell activity [10][9] - The Lyell LyFE Manufacturing Center™ has the capacity to produce over 1,200 CAR T-cell doses at full capacity [13]

Amazon (AMZN 1.81%) looks like one of the most exciting stocks to own over the next several decades. But don't be fooled: This excitement has nothing to do with the company's e-commerce business that currently contributes most of its revenue. Instead, there's another business segment that most investors aren't familiar with. This division should grow by leaps and bounds for years to come thanks to a massive rise in artificial intelligence spending. Amazon is one of the best AI stocks right now Right now, Am ...

Highlights: Courvan Trend infill drilling results intersected near-surface gold zones with significant grades up to 6.2 g/t Au over 4.9 metres, including 26.8 g/t Au over 1.0 metres and thick gold zones, including an intersection of 3.1 g/t Au over 17.0 metres, including 14.1 g/t Au over 2.0 metres.The recently completed 50,000-metre winter infill drilling program was designed to support the upcoming 2025 Pre-Feasibility Study, which is expected by year-end. TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Probe ...

Company Performance - CrowdStrike's stock has achieved a 25% price return since the last coverage, outperforming the S&P 500's 13% price gain despite a July 2024 outage [1] Investment Thesis - The investment thesis for CrowdStrike is based on its cloud-first, AI-native Falcon platform, which is positioned as a modular cybersecurity product [1]

Committed to growing green energy and boosting distributions Operating in 25 countries, Brookfield Renewable Corporation (BEPC 0.59%) has emerged as a dominant force in clean energy. From solar to wind to hydropower, the company maintains a sizable portfolio with about $126 billion in assets under management. While Brookfield Renewable isn't exactly a household name, many income investors are likely familiar with the company's history of rewarding shareholders. This, coupled with the stock's 4.7% forward-yi ...

The Kroger Co. KR will release its first-quarter financial results before the opening bell on Friday, June 20. Considering buying KR stock? Here's what analysts think: Read This Next: Photo via Shutterstock Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. Today's Best Fi ...

New Sapiens CoreSuite release empowers life insurers, agents, customers, and administrators with greater speed, intelligence, and deeper customer engagement via gen AI Agents, customers, and administrators will benefit from generative AI (Gen AI)-powered chatbots; machine learning (ML)-driven lead generation; and predictive tools for buying propensity, product recommendations, and next-best actions. The ability to deliver highly personalized offers will help life insurers deepen customer engagement. ROCHELL ...

Dubai, June 17, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), is pleased to announce that it has appointed Vitaly Shmakov as the Acting General Counsel, based in VEON’s headquarters in the Dubai International Financial Center, effective July 1, 2025. Vitaly Shmakov is currently serving as Group Director of M&A and Strategic Transactions at VEON. Since joining the Company in 2016, he has held various roles, including Deputy General Counsel for Corporate, M&A and Strate ...

Dubai, June 17, 2025: VEON Ltd. (Nasdaq: VEON; the “Company” or “VEON”), a global digital operator, today announces that Omiyinka Doris has chosen to step aside from her role as Group General Counsel of the Company effective July 1, 2025. Ms. Doris will continue as a strategic advisor to the Group Chief Executive Officer and will remain based in Amsterdam. Ms. Doris has worked with VEON for a decade, first as Deputy General Counsel, SEC/Disclosure, Finance and Governance, then as Acting Group General Counse ...

Nvidia could lose 100% of its sales to China The ongoing trade war with China brought several challenges to Nvidia's current business model. Restrictions on open-source Chinese AI models including DeepSeek and Qwen could inhibit AI demand from consumers and businesses, resulting in less demand for GPUs, and thus less demand for Nvidia's products. When it comes to AI stocks, Nvidia (NVDA 1.71%) is king. Its graphics processing units, or GPUs, are widely considered the best in the industry. And because the AI ...